MedCAC To Examine ESAs In Chronic Kidney Disease, Pharmacogenomic Testing In Cancer
The usage of erythropoiesis stimulating agents outside the renal setting is already subject to coverage limitations in Medicare.
The usage of erythropoiesis stimulating agents outside the renal setting is already subject to coverage limitations in Medicare.